Subject(s)
ATP Binding Cassette Transporter, Subfamily B , Attention Deficit Disorder with Hyperactivity , Cholestasis, Intrahepatic , Humans , ATP Binding Cassette Transporter, Subfamily B/deficiency , Attention Deficit Disorder with Hyperactivity/drug therapy , Cholestasis, Intrahepatic/diagnosis , Cholestasis, Intrahepatic/drug therapy , DextroamphetamineSubject(s)
Binge-Eating Disorder , Bipolar Disorder , Central Nervous System Stimulants , Humans , Lisdexamfetamine Dimesylate/adverse effects , Binge-Eating Disorder/complications , Binge-Eating Disorder/diagnosis , Binge-Eating Disorder/drug therapy , Bipolar Disorder/complications , Bipolar Disorder/diagnosis , Bipolar Disorder/drug therapy , Central Nervous System Stimulants/adverse effects , Treatment OutcomeSubject(s)
Acute Kidney Injury/chemically induced , Antimanic Agents/toxicity , Antipsychotic Agents/adverse effects , Clozapine/adverse effects , Lithium Compounds/toxicity , Psychotic Disorders/drug therapy , Self-Injurious Behavior/drug therapy , Adult , Antimanic Agents/administration & dosage , Antipsychotic Agents/administration & dosage , Clozapine/administration & dosage , Female , Humans , Lithium Compounds/administration & dosageSubject(s)
Antidepressive Agents, Second-Generation/adverse effects , Borderline Personality Disorder/drug therapy , Hyponatremia/chemically induced , Naltrexone/pharmacology , Narcotic Antagonists/pharmacology , Self-Injurious Behavior/drug therapy , Venlafaxine Hydrochloride/adverse effects , Adult , Borderline Personality Disorder/complications , Female , Humans , Naltrexone/administration & dosage , Narcotic Antagonists/administration & dosage , Self-Injurious Behavior/etiologySubject(s)
Antimanic Agents/adverse effects , Antitubercular Agents/adverse effects , Bipolar Disorder/drug therapy , Latent Tuberculosis/drug therapy , Rifampin/adverse effects , Valproic Acid/adverse effects , Antimanic Agents/blood , Antimanic Agents/therapeutic use , Antitubercular Agents/therapeutic use , Bipolar Disorder/complications , Drug Interactions , Humans , Latent Tuberculosis/complications , Male , Middle Aged , Rifampin/therapeutic use , Valproic Acid/blood , Valproic Acid/therapeutic useABSTRACT
Inflammatory myopathies, including polymyositis (PM), may add risk to electroconvulsive therapy (ECT) due to muscle sensitivity to depolarizing neuromuscular agents. In addition, previously published case series have shown elevations in creatine phosphokinase (CPK), an index of PM disease severity, in patients without muscle disease receiving ECT. We report the case of a 74-year-old female who developed initial onset of depression after steroid treatment for biopsy-proven PM. After she failed to respond to trials of antidepressant medications, she was treated with 21 inpatient and outpatient sessions of ECT over 2 years. Each course of treatment was effective for her depression without worsening symptoms of muscle disease activity. Two previous cases have described the use of ECT in patients with inflammatory myopathies, but our case is the first to report maintenance phase treatment with CPK monitoring.
